Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA)
NCT03275285Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2017
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Oct 2017; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03275285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275285.